Dermata Therapeutics Inc
XNAS:DRMA 4:00:00 PM EDT
| Market Cap (Intraday) | 4.75M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $1.25 |
| 50-Day MA | $1.31 |
| 200-Day MA | $1.56 |
Dermata Therapeutics Inc Stock, XNAS:DRMA
3525 Del Mar Heights Road, Suite 322, San Diego, California 92130
United States of America
Phone: +1.858.800.2543
Number of Employees: 8
Description
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. Its product pipeline includes DMT310, DMT400, and DMT410. The company was founded by David F. Hale and Gerald T. Proehl on December 8, 2014 and is headquartered in San Diego, CA.